Lilly Invests In MiNA To Fund Protein-Upregulating RNA Programs

  • Eli Lilly And Co LLY is set to invest $15 million in its small activating RNA (saRNA) partner, MiNA Therapeutics. 
  • The investment comes two months after Lilly agreed to pay $25 million upfront to work with MiNA on up to five targets.
  • MiNA will use the money to advance its internal pipeline of saRNA therapeutics, led by a drug designed to cut immunosuppression by raising levels of the C/EBP-⍺ master regulator of myeloid cell differentiation.
  • Price Action: LLY shares are up 0.05% at $234.07 during the market session on the last check Tuesday.
Loading...
Loading...
LLY Logo
LLYEli Lilly and Co
$771.00-0.24%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
30.46
Growth
99.77
Quality
89.15
Value
3.68
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...